EUCTR2010-019925-33-DE进行中（未招募）不适用
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 940
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Provision of signed and dated informed consent before initiation of any study-related procedures.
- •The patient must have a clinical diagnosis of major depressive disorder (MDD) with inadequate response to no more than one antidepressant.
- •Out-patient status at enrollment and randomization.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 893
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 47
排除标准
- •Patients with a lifetime history of bipolar disorder, psychotic disorder or post-traumatic stress disorder.
- •Patients with a history of suicide attempts in the past year and/or seen by the investigator as having a signficant history of risk of suicide or homicide.
- •History of renal insufficiency or impairment or conditions that could affect absorption or metabilism of the investigationl product in this patient population
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hypercholesterolemia at Moderately High Risk and High Risk for CHD. - Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus AtorvastatiMedDRA version: 9.1Level: LLTClassification code 10020604Term: HypercholesterolemiaHypercholesterolemiaEUCTR2007-004448-60-BEMerck Sharp & Dohme BV1,281
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups ofTC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patientswith Major Depressive Disorder Who Exhibit an Inadequate Response toAntidepressant TherapyAdjunct treatment to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapyMedDRA version: 12.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSEUCTR2010-020140-36-SKAstraZeneca AB2,236
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Statin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia. - Extended Release Niacin/Laropiprant – LipidsHypercholesterolemia or Mixed DyslipidemiaMedDRA version: 9.1 Level: LLT Classification code 10020604 Term: HypercholesterolemiaEUCTR2007-002017-39-DKMerck & Co., Inc.1,250
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patient with Metabolic Syndrome and Hypercholesterolemia at High Risk for Coronary Heart Disease - NDmetabolic syndrome and hypercholesterolemiaMedDRA version: 6.1 Level: SOC Classification code 10007541EUCTR2006-006497-17-ITMERCK SHARP DOHME1,120
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Statin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia. - Extended Release Niacin/Laropiprant – LipidsHypercholesterolemia or Mixed DyslipidemiaMedDRA version: 9.1Level: LLTClassification code 10020604Term: HypercholesterolemiaEUCTR2007-002017-39-HUMerck & Co., Inc.1,250